Cannabis Stocks Soar After Trump Endorses CBD for Seniors, Mentions Medicaid

Markets leapt Monday after former President Donald Trump posted a video
promoting the benefits of hemp-derived CBD for older Americans and called
for expanded Medicare/Medicaid access to CBD. The move sent pot stocks—and
broader investor expectations—into overdrive.
*What the video says and why it hit*

In the nearly three-minute clip, Trump said CBD is a “gamechanger” for pain
and stress relief among seniors, and urged physician education and expanded
government healthcare coverage. He framed the conversation around
delivering real options to older voters, and invoked his 2018 Farm Bill
signature as precedent. The video was produced by the pro-cannabis
nonprofit Commonwealth Project and released across social media platforms.

The market reaction was immediate: cannabis ETFs, major cultivators, and
consumer product companies all posted gains—reflecting how sensitive this
sector is to political signaling, even absent concrete policy changes.
*The investor mindset: hope vs reality*

Much of today’s rally is speculative: investors are betting on possible
future reforms—rescheduling, insurance expansion, or regulatory loosening.
But the shift from rhetoric to regulation is rarely seamless. Without
statutory changes, Trump’s statements don’t override existing law.

The surging valuations also underscore how narrow the leeway is: many
cannabis companies remain unprofitable, struggling under tax burdens,
compliance costs, and banking challenges. A policy nudge can spark
optimism—but long-term gains depend on structural change, not just
headlines.
*What would actual reform look like?*

- *Schedule reclassification:* If marijuana moves to Schedule III, it
could unlock tax deductions, insurance coverage, and broader financial
legitimacy.
- *FDA & insurance framework for CBD:* If federal health programs begin
covering CBD, it would legitimize the market and expand demand well beyond
wellness shops into medical corridors.
- *Regulatory clarity & safety rules:* Deeper labeling, dosing, FDA
standards, and enforcement regimes would need to accompany policy shifts to
prevent miscommunication or backlash.
- *Gradual institutional entry:* Even under reform, many institutional
investors and banks will adopt cautious, staged approaches to cannabis
exposure—especially in states with divergent regulations.

*Risks beneath the surface*

- *Electoral posturing:* Political endorsements are often timed for
impact; momentum depends on legislative backing (and party alignment).
- *DEA inertia:* Trump’s DEA administrator, Terrance Cole, left cannabis
rescheduling off his published priorities—suggesting agency leadership may
lag behind political gestures.
- *Market fatigue:* Over time, valuations built on promises can slide if
real change lags. Investors may start pricing in “political risk discount”
if reforms stall.
- *Divisive backlash:* As approvals expand, some constituencies may push
back—especially if THC gets entangled in coverage debates.

*Moving from hype to policy*

The cannabis sector is effectively living in the “expectation
economy”—moments like Trump’s video shift sentiment, but enduring gains
will depend on measurable legislative or administrative follow-through. The
most durable winners won’t be juiced by the tweet — they’ll be those who
align strategy with policy, compliance, and innovation.

[image: 👉] *Audience Question:*

Was Trump’s CBD video a turning point—or just another headline moment? What
concrete reform would you demand now to translate market optimism into
sustainable industry change?

The post Cannabis Stocks Soar After Trump Endorses CBD for Seniors,
Mentions Medicaid appeared first on Merry Jane.